Yttrium-90: Application in Nuclear Medicine and Production in Radionuclide Generators

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Radiochemistry

• Publication date

  2025-10-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1134/S1066362225050017
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Utility of low specific activity 90Y produced in a medium flux research reactor in the preparation of radioactive patch for the treatment of skin ailments

  2025cited by this paper
• Sorption Characteristics and Chromatographic Separation of 90Y3+ from 90Sr2+ from Aqueous Media by Chelex-100 (Anion Ion Exchange) Packed Column

  2024cited by this paper
• Pentixather: paving the way for radioligand therapy in oncohematology

  2024cited by this paper
• Transarterial Radioembolization (TARE) Global Practice Patterns: An International Survey by the Cardiovascular and Interventional Radiology Society of Europe (CIRSE)

  2024cited by this paper
• CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges

  2023cited by this paper
• Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies

  2023cited by this paper
• [68Ga]/[90Y]FAPI-46: Automated production and analytical validation of a theranostic pair.

  2022cited by this paper
• EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds

  2022cited by this paper
• [177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer

  2022cited by this paper
• Radiometal-theranostics: the first 20 years*

  2022cited by this paper
• Choosing optimal treatment organisation strategy for unresectable liver cancer: case of Moscow region

  2022cited by this paper
• Microspheres Used in Liver Radioembolization: From Conception to Clinical Effects

  2021cited by this paper
• Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels

  2021cited by this paper
• Perspectives on metals-based radioimmunotherapy (RIT): moving forward

  2021cited by this paper
• Selective permeation of 90Y from a mixture of 90Y/90Sr through diglycolamide impregnated supported liquid membranes.

  2021cited by this paper
• Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies

  2021cited by this paper
• 90Y/177Lu-DOTATOC: From Preclinical Studies to Application in Humans

  2021cited by this paper
• Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview

  2021cited by this paper
• Initial Clinical Experience with 90Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients

  2021cited by this paper
• The use of yttrium in medical imaging and therapy: historical background and future perspectives.

  2020cited by this paper
• Radiopharmaceutical therapy in cancer: clinical advances and challenges

  2020cited by this paper
• Tandem peptide receptor radionuclide therapy using 90Y/177Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience

  2020cited by this paper
• History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma

  2019cited by this paper
• A guide to 90Y radioembolization and its dosimetry.

  2019cited by this paper
• Liver Radioembolization: a New Chapter in Russian Oncology

  2019cited by this paper
• Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention

  2019cited by this paper
• 90Y-DOTATOC Dosimetry–Based Personalized Peptide Receptor Radionuclide Therapy

  2018cited by this paper
• Dosimetry Estimate and Initial Clinical Experience with 90Y-PSMA-617

  2018cited by this paper
• Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein

  2018cited by this paper
• The Beginning and Development of the Theranostic Approach in Nuclear Medicine, as Exemplified by the Radionuclide Pair 86Y and 90Y

  2017cited by this paper
• Labelling of 90Y- and 177Lu-DOTA-Bioconjugates for Targeted Radionuclide Therapy: A Comparison among Manual, Semiautomated, and Fully Automated Synthesis

  2017cited by this paper
• Separation of Yttrium-90 from Strontium-90 by Extraction Chromatography Using Combined Sr Resin and RE Resin

  2016cited by this paper
• A comparative evaluation of the chelators H4octapa and CHX-A″-DTPA with the therapeutic radiometal (90)Y.

  2016cited by this paper
• Correlation of clinical outcomes with bremsstrahlung and Y-90 PET/CT imaging findings following Y-90 radiosynoviorthesis: a prospective study

  2016cited by this paper
• Zevalin(®) (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned?

  2016cited by this paper
• [177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer

  2015cited by this paper
• Theranostic Imaging of Yttrium-90

  2015cited by this paper
• Radiochemistry, pre-clinical studies and first clinical investigation of 90Y-labeled hydroxyapatite (HA) particles prepared utilizing 90Y produced by (n,γ) route.

  2015cited by this paper
• Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours

  2014cited by this paper
• Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study

  2013cited by this paper
• The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours

  2013cited by this paper
• 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging.

  2012cited by this paper
• Sodium titaniumsilicate as ion exchanger: synthesis, characterization and application in separation of 90Y from 90Sr

  2012cited by this paper
• Yttrium-90 DOTATOC therapy in GEP-NET and other SST2 expressing tumors: a selected review

  2011cited by this paper
• PET Imaging of CXCR4 Receptors in Cancer by a New Optimized Ligand

  2011cited by this paper
• Quinolinephosphomolybdate as ion exchanger: synthesis, characterization, and application in separation of 90Y from 90Sr

  2011cited by this paper
• Separation of the 90Sr-90Y pair with cerium(IV) iodotungstate cation exchanger.

  2009cited by this paper
• One column operation for (90)Sr/(90)Y separation by using a functionalized-silica.

  2009cited by this paper
• Development of an electrochemical 90 Sr-90 Y generator for separation of 90 Y suitable for targeted therapy.

  2008cited by this paper
• Studies on the Development of a Two Stage SLM System for the Separation of Carrier‐free 90Y using KSM‐17 and CMPO as Carriers

  2007cited by this paper
• Characterization of Extraction of Chromatographic Materials Containing Bis(2‐ethyl‐1‐hexyl)Phosphoric Acid, 2‐Ethyl‐1‐Hexyl (2‐Ethyl‐1‐Hexyl) Phosphonic Acid, and Bis(2,4,4‐Trimethyl‐1‐Pentyl)Phosphinic Acid

  2007cited by this paper
• Simple and safe production of yttrium-90 from a new type of 90Sr/90Y generator

  2005cited by this paper
• Inorganic ion-exchangers: Their role in chromatographic radionuclide generators for the decade 1993–2002

  2005cited by this paper
• Separation of 90Y from 90Sr using zirconium vanadate as the ion exchanger.

  2004cited by this paper
• Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate

  2003cited by this paper
• DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals

  2003cited by this paper
• The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy

  2003cited by this paper
• Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine

  2002cited by this paper
• 111In- and 90Y-DOTA-Lanreotide: Results and implications of the MAURITIUS trial

  2002cited by this paper
• Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of 86Y-DOTATOC and 111In-DTPA-octreotide

  2001cited by this paper
• Uptake kinetics of the somatostatin receptor ligand [86Y]DOTA-dPhe1-Tyr3-octreotide ([86Y]SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue

  1999cited by this paper
• Yttrium-90-labelled somatostatin-analogue for cancer treatment.

  1998cited by this paper
• Separation of 90Y from 90Sr on Crystalline Antimonic(V) Acid

  1995cited by this paper
• Continuous cultures of fused cells secreting antibody of predefined specificity

  1975cited by this paper
• Use of atomic energy for peaceful purposes

  1957cited by this paper
• THE CHINESE PHARMACOPOEIA.

  1930cited by this paper

• Multifunctional carrier based on biocompatible artificial anionic polysaccharide, cross-linked with 90Y(III) ions and with a built-in antitumor agent.

  2026cites this paper